Log in with your email address username.

×

[Correspondence] Questions in the design of ANSWER

Trials including participants with advanced liver disease are challenging. In the open-label ANSWER trial, Paolo Caraceni and colleagues (May 31, p 2417)1 aimed to assess the effect of long-term albumin administration in decompensated cirrhosis on overall survival. The authors conclude that albumin administration is associated with improved overall survival. However, it is unclear whether this finding is robust.

email